Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,475.09 +14.61 (+0.27%) Dow
39,169.52 +50.66 (+0.13%) Nasdaq
17,879.30 +146.70 (+0.83%) Bitcoin USD
62,669.78 -13.95 (-0.02%) CMC Crypto 200
1,339.04 -5.47 (-0.41%)
GILD Jun 2024 95.000 call
- Simply Wall St.
Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- GuruFocus.com
Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
Following this sale, the insider now owns 96,380 shares of Gilead Sciences Inc. Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's portfolio includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
- Insider Monkey
Should You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) appreciated 10.17% outperforming the Russell 1000 Value Index’s 8.99%. Stock selection in the Information Technology and Communication Services sectors was the […]
